Company intelligence / Profile preview

Specific Diagnostics

San Jose, California, United States

Ownership: Private
Employees: ~61
Development stage: Other

Overview

Specific Diagnostics developed rapid in vitro diagnostic systems for detection, identification, and antibiotic susceptibility testing of microorganisms directly from positive blood cultures, significantly accelerating time-to-result compared to traditional methods. Their Reveal Rapid AST System delivers phenotypic AST results in an average of 5 hours, enabling earlier optimal antibiotic therapy for patients with sepsis and bloodstream infections[4][6].

Therapeutic areas: Infectious Diseases
Modalities: Device
Industry: Metabolite Diagnostics

Partnerships

bioMérieux (co-exclusive distribution and later acquisition)[5]Henry Ford Health System (clinical study)[7]National Institute of Allergy and Infectious Diseases (NIAID, grant funding)[3][7]

Beyond the preview

Go deeper on Specific Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Specific Diagnostics.

Explore the full profile